TOP 100 INDIAN INNOVATIONS
with focus on Healthcare Innovations

Protonated Bio-Adhesive Polymer Technology (PBT) – Axio Biosolutions, Bangalore Leo Mavely is Founder & CEO of Axio Biosulutions. A graduate in Applied Bioengineering from MDH, Rohtak and mentored at Nirma Lbs. In the college he worked on developing Microfluidic devices like Micropumps, Microcentrifuges from biopolymers Poly Di-Methyl Siloxane. These devices were developed on a lab scale without using costly techniques such as Photolithography. The working model was developed with the help of Dr. Amit Astana (Mentor) as part of 5 member team. The project won award at IIT-Roorkee Techfest 2006. Leo was featured in the list of 40 under 40 emerging business leaders by Fortune Magazine

consecutively 2016, 2017, 2018 and 2019 and in the list of 35 under 35 entrepreneurs by Entrepreneur magazine in 2020. Leo was honored as a Champion of Change by Prime Minister, Shri Narendra Modi in 2017. He was the recipient of Silicon valley challenges 2014, Anjani Mashelkar Inclusive Innovation Award 2013, CNBC Samsung Social Innovation Award 2012 and was invited speaker at Indian Science Congress 2010. https://www.linkedin.com/in/loemavely/

Technology

The concept of clamping a bleeding vessel with an instrument before typing it off is generally attributed to Galen (second century AD). This method of hemostasis was largely forgotten until it was rediscovered by the French barber-surgeon Ambroise Paré in the 16th century. QuikClot is a proprietary hemostatic technology consisting of a nonwoven material impregnated with kaolin, an inorganic mineral that activates factor XII1 which in turn accelerates the body’s natural clotting ability. This bleeding control solution creates a robust clot6, 7 to control bleeding fast.

Innovation

Axio Biosolutions employs the proprietary Protonated Bioadhesive Polymer technology (PBT) to make its biopolymerbased hemostats, drug delivery systems and scaffolds with tailorable bio-adhesive properties. The essence of PBT technology lies in maximizing the bio-adhesive properties of native chitosan without chemical modifications in its backbone. Axiostat is the first commercial product based on the PBT. Its uniform microscopic porous structure provides a unique molecular chemistry of chitosan within the matrix, which helps in retaining its positive charge for prolonged duration and even under physiological conditions. This method of bleeding control is robust enough that it works irrespective of the natural clotting factors, hence PBT is successful even in patients taking the blood thinning medications. Lastly the enhanced cationic charge provided by the PBT biopolymer also provides strong antimicrobial properties to the material and restricts entry of external bacteria into the wound site.

Patents

Mucoadhesive preparations, methods and applications thereof, Patent number: 11491107, granted 2022. COMPOSITE DRESSINGS, MANUFACTURING METHODS AND APPLICATIONS THEREOF, Publication number: 20210252182, Granted 2021 Co-Inventor Kiran Sonaje was Head of R&D: https://www.linkedin.com/in/kiransonaje/

Commercialisation

https://axiobio.com/

Axio developed Axiostat – India’s First and only USFDA approved trauma hemostat that stops life threatening bleeding instantly. Axiostat is being used by soldiers in over 350 battallions across India to manage bleeding from injuries in battlefield. It is approved in over 40 countries and used by major armed forces globally. Axiostat is a bioactive haemostatic dressing that works on a unique charge-based mechanism to stop the bleeding quickly.

The startup announced another USFDA 510K thousands clearance for Axiostat Patch for control of moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more. This clearance opens the door to enter markets such as Vascular closure, Hemodialysis, EMS and Military segments in the US soon. Axiostat had also received CE mark in Europe earlier and is also approved in over 40 countries worldwide. Over half a million units have been deployed since inception globally especially in battlefields to control bleeding from trauma injuries and in hospitals to control for vascular closure bleeding.